Effect of low-dose bromocriptine in treatment of psychosis: the dopamine autoreceptor-stimulation strategy.
Bromocriptine (0.5-6.0 mg/day) was administered to seven unmedicated chronic schizophrenic and two schizoaffective patients. Transient slight improvement was noted in four patients and marked improvement in one other. Clinical improvement was associated with nausea and drowsiness. These doses of bromocriptine stimulated serum growth hormone and inhibited serum prolactin levels in some subjects. These results suggest that bromocriptine may stimulate dopamine autoreceptors and, through this mechanism, attenuate symptoms in a small proportion of psychiatric patients.
D001923:Brain Chemistry / Q000187:drug effects; D001971:Bromocriptine / Q000009:adverse effects / Q000627:therapeutic use*; D005260:Female; D013006:Growth Hormone / Q000097:blood; D006801:Humans; D008297:Male; D011388:Prolactin / Q000097:blood; D011569:Psychiatric Status Rating Scales; D011618:Psychotic Disorders / Q000188:drug therapy* / Q000378:metabolism; D011954:Receptors, Dopamine / Q000187:drug effects*
D011954:Receptors, Dopamine; D001971:Bromocriptine; D011388:Prolactin; D013006:Growth Hormone